Navigation Links
Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Date:2/15/2008

umans. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as amended, and most current Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved. Poniard and Poniard Pharmaceuti
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
2. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
3. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
4. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
5. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
6. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
7. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 21, 2014 Influenza will affect as many ... the United States as high as ... to spread is from person to person in respiratory droplets ... serve way of death, but kills much fewer people each ... done by human fluids including sweat, saliva, blood and other ...
(Date:10/22/2014)... and AUSTIN, Texas , Oct. ... LLC today announced they have entered into a ... immunotherapies designed to target cancers. PhosImmune ... displayed on the surfaces of tumor cells in ... (PTTs), derived from proteins that play a role ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014   ... and WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials ... Under the terms of the collaboration, Foundation Medicine will ... of Foundation Medicine,s FoundationOne® assay at the WuXi Genome ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
... Healthy Advice ® Networks, the nation,s ... programs at point-of-care, announces that their partner, MediaForce ... the Food and Drug Administration,s campaign, educating consumers ... relievers. Partnering with MediaForce PR, Healthy Advice ...
... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... meeting of shareholders held in Hong Kong on August 9, ... the re-election of incumbent Class A directors Xiaozhong Liu, Ying ... term. About WuXi PharmaTechWuXi PharmaTech is a ...
Cached Medicine Technology:Healthy Advice® Networks Partners With MediaForce PR to Deliver Public Service Announcements to Educate Consumers About Appropriate Use of Prescription Medications 2Healthy Advice® Networks Partners With MediaForce PR to Deliver Public Service Announcements to Educate Consumers About Appropriate Use of Prescription Medications 3
(Date:10/22/2014)... October 22, 2014 Richard Carlson, Managing ... industry leader with over 25 years experience. Mr. ... in the areas related to EDI, B2B Commerce, RFID ... an Editorial Advisory Board member for Pharmaceutical Commerce Magazine ... Blue Fin Group is a management and technology consulting ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Two sisters in ... heart damage. Ilina and Medha Krishen use electronic ... sounds of trouble in breathing patterns or heartbeats. ... in Michigan, wanted to find a way to detect ... pollutants. Using an electronic stethoscope, Ilina recorded one breath ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, ... tightened guidelines for health workers treating Ebola patients, now requiring ... a respirator at all times. The U.S. Centers for ... after two Dallas nurses contracted Ebola while caring for the ... Thomas Eric Duncan. Nina Pham is currently being treated for ...
(Date:10/20/2014)... Pittsburgh, PA (PRWEB) October 20, 2014 ... new, minimally-invasive procedure that enables physicians to repair a ... , The MitraClip system, developed by ... regurgitation (MR), a progressive and life-threatening condition in which ... allowing blood to flow backward from the heart’s left ...
(Date:10/20/2014)... 20, 2014 T.E.N., a technology ... announced today that William H. Murray, renowned author ... ISE® Luminary Leadership Award winner. Presented annually, the ... an outstanding leader and industry practitioner for his ... advancing the information security industry. , Formerly with ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... from Boston University School of Medicine (BUSM) have ... share the majority of the same genes with ... dysregulate the expression of circadian genes and those ... ,The circadian factors, including the principal circadian hormone ...
... of the anti-malarial drug hydroxychloroquine may help reduce ... diabetes . ,Type 2 diabetes mellitus ... its prevalence has been increasing. ... inexpensive treatment for an autoimmune disease such as ...
... A Canadian researcher has unearthed the relationship between high ... of circumstances , including among individuals with heart disease. ... Montreal Heart Institute, currently affiliated with the Universite de ... typically suffer chest pain during exercise, and may be ...
... admitted that she fears that an innocent kiss will result in ... she has major trust issues, and that she doesn't just make ... a waste of her time and kisses. ,Clarkson added ... ,"I have major trust issues. I just don't make ...
... looming global shortage of phosphorus can be dealt with by ... of the Institute for Sustainable Futures at the University of ... may finish in about 50 years. She believes that if ... a year is recycled, the danger of running out of ...
... ash and smoke into the air, seen in the ... causing more than 8000 people to be evacuated amid ... ,Officials raised the alert to the highest level on Tuesday ... Maluku, started spitting out flaming material, indicating magma was approaching ...
Cached Medicine News:Health News:Cocaine Exposure can Alter Neuronal Development in Zebrafish 2Health News:Anti-malarial Drug may Help Reduce Risk of Diabetes in Rheumatoid Arthritis Patients 2Health News:Urine is a Rich Source of Phosphorus 2Health News:Envisat Captured Breath of Volcano 2
... is a versatile, low profile, titanium ... Minimal instrumentation needed for implantation. Reduction ... Monosegmental and multisegmental applications. Worldwide market ... implantations. Tested in accordance with AS ...
... The ISOLA/VSP Spine System is a comprehensive ... that can be used for both deformity ... understanding of the spine in 3-dimensions, the ... translation techniques to correctly align and stabilize ...
Transcranial and peripheral vascular doppler system....
One channel transcranial doppler with multigate, emboli detection, monitoring module and tests for hemodynamic evaluation. Looki 1TC is suitable as well for routine diagnosis as for monitoring in ope...
Medicine Products: